Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 276, Issue 1 39-1, 1999, Pages

  Drucker, Daniel J ^a,c   Yusta, Bernardo ^a   Boushey, Robin P ^a   DeForest, Lorraine ^a   Brubaker, Patricia L ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Epithelium; Growth factor; Inflammation; Inflammatory bowel disease; Intestine

Indexed keywords

DEXTRAN SULFATE; GLUCAGON LIKE PEPTIDE; INTERLEUKIN 1; (GLYCYL GLYCYL)GLP 2; (GLYCYL-GLYCYL)GLP-2; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLITIS; COLON INJURY; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; FEMALE; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE REGENERATION; ULCERATIVE COLITIS; ANIMAL; BAGG ALBINO MOUSE; CELL DIVISION; CHEMICALLY INDUCED DISORDER; COLON; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; INTESTINE MUCOSA; MOUSE STRAIN; PATHOLOGY; WEIGHT REDUCTION;

ANIMALS; CELL DIVISION; COLITIS; COLON; DEXTRAN SULFATE; FEMALE; HUMANS; INTERLEUKIN-1; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; PEPTIDES; WEIGHT LOSS;

EID: 0032621235     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.1999.276.1.g79     Document Type: Article

References (56)

1. Axelsson, L. G., E. Landstrom, T. J. Goldschmidt, A. Gronberg, and A. C. Bylund-Fellenius. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+)-cell depleted, athymic and NK-cell depleted SCID mice. Inflamm. Res. 45: 181-191, 1996.
2. Bennett, C. F., D. Kornbrust, S. Henry, K. Stecker, R. Howard, S. Cooper, S. Dutson, W. Hall, and H. I. Jacoby. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther. 280: 988-1000, 1997.
3. Bjorck, S., E. Jennische, A. Dahlstrom, and H. Ahlman. Influence of topical rectal application of drugs on dextran sulfate-induced colitis in rats. Dig. Dis. Sci. 42: 824-832, 1997.
4. Bloom, S. R., and J. M. Polak. The hormonal pattern of intestinal adaptation [a major role for enteroglucagon]. Scand. J. Gastroenterol. 17: 93-103, 1982.
5. Bradley, P. P., D. A. Priebat, R. D. Christensen, and G. Rothstein. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78: 206-209, 1982.
6. Brubaker, P. L., A. Crivici, A. Izzo, P. Ehrlich, C.-H. Tsai, and D. J. Drucker. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide 2. Endocrinology 138: 4837-4843, 1997.
7. Brubaker, P. L., A. Izzo, M. Hill, and D. J. Drucker. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am. J. Physiol. 272 (Endocrinol. Metab. 35): E1050-E1058, 1997.
8. Campos, R. V., Y. C. Lee, and D. J. Drucker. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134: 2156-2164, 1994.
9. Campos, R. V., L. Zhang, and D. J. Drucker. Differential expression of RNA transcripts encoding unique carboxy-terminal sequences of human parathyroid-related peptide. Mol. Endocrinol. 9: 1656-1666, 1994.
10. Chance, W. T., T. Foley-Nelson, I. Thomas, and A. Balasubramaniam. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am. J. Physiol. 273 (Gastrointest. Liver Physiol. 36): G559-G563, 1997.
11. Cheeseman, C. I. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am. J. Physiol. 273 (Regulatory Integrative Comp. Physiol. 42): R1965-R1971, 1997.
12. Cheeseman, C. I., and R. Tsang. The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal hexose transport. Am. J. Physiol. 271 (Gastrointest. Liver Physiol. 34): G477-G482, 1996.
13. Chomczynski, P., and N. Sacchi. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Chem. 162: 156-159, 1987.
14. Cooper, H. S., S. N. Murthy, R. S. Shah, and D. J. Sedergran. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69: 238-249, 1993.
15. Dieleman, L. A., B. U. Ridwan, G. S. Tennyson, K. W. Beagley, R. P. Bucy, and C. O. Elson. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643-1652, 1994.
16. Domek, M. J., F. Iwata, E. I. Blackman, J. Kao, M. Baker, A. Vidrich, and F. W. Leung. Anti-neutrophil serum attenuates dextran sulfate sodium-induced colonic damage in the rat. Scand. J. Gastroenterol. 30: 1089-1094, 1995.
17. Drucker, D. J. Intestinal growth factors. Am. J. Physiol. 273 (Gastrointest. Liver Physiol. 36): G3-G6, 1997.
18. 2]glucagon-like peptide 2. Am. J. Physiol. 273 (Gastrointest. Liver Physiol. 36): G1252-G1262, 1997.
19. Drucker, D. J., P. Ehrlich, S. L. Asa, and P. L. Brubaker. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA 93: 7911-7916, 1996.
20. Drucker, D. J., Q. Shi, A. Crivici, M. Sumner-Smith, W. Tavares, M. Hill, L. DeForest, S. Cooper, and P. L. Brubaker. Regulation of the biological activity of glucagon-like peptide 2 by dipeptidyl peptidase IV. Nat. Biotechnol. 15: 673-677, 1997.
21. Egger, B., F. Procaccino, J. Lakshmanan, M. Reinshagen, P. Hoffman, A. Patel, W. Reuben, S. Gnanakkan, L. Liu, L. Barajas, and V. E. Eysselein. Mice lacking transforming growth factor a have an increased susceptibility to dextran sulfate-induced colitis. Gastroenterology 113: 825-832, 1997.
22. Elson, C. O., R. B. Sartor, G. S. Tennyson, and R. H. Riddell. Experimental models of inflammatory bowel disease. Gastroenterology 109: 1344-1367, 1995.
23. Emmrich, J., M. Seyfarth, W. E. Fleig, and F. Emmrich. Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet 1: 570-571, 1991.
24. Fuller, P. J., D. J. Beveridge, and R. G. Taylor. Ileal proglucagon gene expression in the rat: characterization in intestinal adaptation using in situ hybridization. Gastroenterology 104: 459-466, 1993.
25. Gleeson, M. H., S. R. Bloom, J. M. Polak, K. Henry, and R. H. Dowling. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut 12: 773-782, 1971.
26. Hanauer, S. B. Inflammatory bowel disease. N. Engl. J. Med. 334: 841-848, 1996.
27. Hodin, R. A., S. Meng, and A. Shei. Bombesin maintains enterocyte phenotype in fasted rats. Surgery 116: 426-431, 1994.
28. Hogaboam, C. M., B. A. Vallance, A. Kumar, C. L. Addison, F. L. Graham, J. Gauldie, and S. M. Collins. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J. Clin. Invest. 100: 2766-2776, 1997.
29. Housley, R. M., C. F. Morris, W. Boyle, B. Ring, R. Blitz, J. E. Tarpley, S. L. Aukerman, P. L. Devine, R. H. Whitehead, and G. F. Pierce. Keratinocyte growth factor induced proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J. Clin. Invest. 94: 1764-1777, 1994.
30. Koh, T. J., J. R. Goldenring, S. Ito, H. Mashimo, A. S. Kopin, A. Varro, G. J. Dockray, and T. C. Wang. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. Gastroenterology 113: 1015-1025, 1997.
31. Kojouharoff, G., W. Hans, F. Obermeier, D. N. Mannel, T. Andus, J. Scholmerich, V. Gross, and W. Falk. Neutralization of tumor necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulfate-induced colitis in mice. Clin. Exp. Immunol. 107: 353-358, 1997.
32. Lee, Y. C., R. V. Campos, and D. J. Drucker. Region- and age-specific differences in proglucagon gene expression in the central nervous system of wild-type and glucagon-simian virus-40 T-antigen transgenic mice. Endocrinology 133: 171-177, 1993.
33. Mashimo, H., D.-C. Wu, D. K. Podolsky, and M. C. Fishman. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274: 262-265, 1996.
34. McCall, R. D., S. Haskill, E. M. Zimmerman, P. K. Lund, R. C. Thompson, and R. B. Sartor. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology 106: 960-972, 1994.
35. Minocha, A., C. Thomas, and R. Omar. Lack of crucial role of mast cells in pathogenesis of experimental colitis in mice. Dig. Dis. Sci. 40: 1757-1762, 1995.
36. Murthy, S., N. S. Murthy, D. Coppola, and D. L. Wood. The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis. Inflamm. Res. 46: 224-233, 1997.
37. Ni, J., S. F. Chen, and D. Hollander. Effects of dextran sulfate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 39: 234-241, 1996.
38. Okayasu, I., S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702, 1990.
39. Olson, A. D., E. A. Delbuono, K. N. Bitar, and D. G. Remick. Antiserum to tumor necrosis factor and failure to prevent murine colitis. J. Pediatr. Gastroenterol. Nutr. 21: 410-418, 1995.
40. Onderdonk, A. B., and J. G. Bartlett. The role of bacteria in experimental ulcerative colitis. Am. J. Clin. Nutr. 32: 258-265, 1979.
41. Rajora, N., G. Boccoli, A. Catania, and J. M. Lipton. α-MSH modulates experimental inflammatory bowel disease. Peptides 18: 381-385, 1997.
42. Savendahl, L., L. E. Underwood, K. M. Haldeman, M. H. Ulshen, and P. K. Lund. Fasting prevents experimental murine colitis produced by dextran sulfate sodium and decreases interleukin-1β and insulin-like growth factor I messenger ribonucleic acid. Endocrinology 138: 734-740, 1997.
43. Shintani, N., T. Nakajima, H. Nakakubo, H. Nagai, Y. Kagitani, H. Takizawa, and H. Asakura. Intravenous immunoglobulin (IVIG) treatment of experimental colitis induced by dextran sulfate sodium in rats. Clin. Exp. Immunol. 108: 340-345, 1997.
44. Stack, W. A., S. D. Mann, A. J. Roy, P. Heath, M. Sopwith, J. Freeman, G. Holmes, R. Long, A. Forbes, and M. A. Kamm. Randomised trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 349: 521-524, 1997.
45. Stevens, F. M., R. W. Flanagan, D. O'Gorman, and K. D. Buchanan. Glucagonoma syndrome demonstrating giant duodenal villi. Gut 25: 784-791, 1984.
46. Stronkhorst, A., S. Radema, S. L. Yong, H. Bijl, I. J. Ten Berge, G. N. Tytgat, and S. J. van Deventer. CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut 40: 320-327, 1997.
47. Tang-Christensen, M., P. J. Larsen, R. Goke, A. Fink-Jensen, D. S. Jessop, M. Moller, and S. P. Sheikh. Central administration of GLP-1(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 271 (Regulatory Integrative Comp. Physiol. 40): R848-R856, 1996.
48. Targan, S. R., S. B. Hanauer, S. J. van Deventer, L. Mayer, D. H. Present, T. Braakman, K. L. Dewoody, T. F. Schaible, and P. J. Rutgeerts. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N. Engl. J. Med. 337: 1029-1035, 1997.
49. Taylor, R., D. Beveridge, T. Nakamura, and P. Fuller. Hepatocyte growth factor gene expression after massive small bowel resection: lack of stimulation in lung and liver. Exp. Clin. Endocrinol. 103: 58-62, 1995.
50. Thompson, J. S. Can the intestine adapt to a changing environment? Gastroenterology 113: 1402-1412, 1997.
51. Tsai, C.-H., M. Hill, S. L. Asa, P. L. Brubaker, and D. J. Drucker. Intestinal growth-promoting properties of glucagon-like peptide 2 in mice. Am. J. Physiol. 273 (Endocrinol. Metab. 36): E77-E84, 1997.
52. Tsai, C.-H., M. Hill, and D. J. Drucker. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am. J. Physiol. 272 (Gastrointest. Liver Physiol. 35): G662-G668, 1997.
53. Turton, M. D., D. O'Shea, I. Gunn, S. A. Beak, C. M. B. Edwards, K. Meeran, S. J. Choi, G. M. Taylor, M. M. Heath, P. D. Lambert, J. P. H. Wilding, D. M. Smith, M. A. Ghatei, J. Herbert, and S. R. Bloom. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72, 1996.
54. Wang, T. C., T. J. Koh, A. Varro, R. J. Cahill, C. A. Dangler, J. G. Fox, and G. J. Dockray. Processing and proliferative effects of human progastrin in transgenic mice. J. Clin. Invest. 98: 1918-1929, 1996.
55. Yamada, M., T. Ohkusa, and I. Okayasu. Occurrence of dysplasia and adenocarcinoma after experimental chronic ulcerative colitis in hamsters induced by dextran sulphate sodium. Gut 33: 1521-1527, 1992.
56. Zeeh, J. M., F. Procaccino, P. Hoffmann, S. L. Aukerman, J. A. McRoberts, S. Soltani, G. F. Pierce, J. Lakshmanan, D. Lacey, and V. E. Eysesselein. Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology 110: 1077-1083, 1996.